Key result
Melatonin decreases nocturnal hypertension, improves blood pressure, and reduces platelet aggregation, suggesting a potential therapeutic role in cardiovascular disorders.
Why the study?
Does melatonin improve cardiovascular parameters in humans with cardiovascular disease?
Does melatonin improve cardiovascular parameters in humans with cardiovascular disease?
Melatonin exhibits several beneficial cardiovascular effects in humans, suggesting it warrants evaluation in clinical trials for cardiovascular disorders.
Supports melatonin evaluation in hypertension trials; leaves open effects on clinical outcomes.
The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension, and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.
No takes yet. Share an insight, caveat, or question.
Pandi‐Perumal et al. (2016) conducted a review in Cardiovascular disease. Melatonin was evaluated. Melatonin decreases nocturnal hypertension, improves blood pressure, and reduces platelet aggregation, suggesting a potential therapeutic role in cardiovascular disorders.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: